| TRADING CENTER |
| Flamel Technologies Announces the Initiation of a Phase 2a Clinical Trial of Flamel&#... - Business Wire |
| Last trade | Change/%change | P/E ratio | ||
|---|---|---|---|---|
| JNJ | Johnson & Johnson | 64.74 | 0.41 / 0.64% | 14.14 |
| PFE | Pfizer Inc | 18.75 | 0.14 / 0.74% | 15.75 |
| NVS | Novartis AG | 54.23 | 0.43 / 0.79% | 15.23 |
| 2008 Revenue: | $38.6 M | Headquarters: Venissieux Cedex, |
| Employees: | 284 | CEO: Stephen H. Willard |
| Net Income: | $-12,084,000.0 | Industry: Pharmaceuticals |
| Market Cap: | $181.7 M | Website: www.flamel-technologies.fr |
| Symbol | Price | Change/%Change | Prev. close | High | Low | Last Update | More Info |
|---|---|---|---|---|---|---|---|
| FLML | 7.59 | +0.09 / +1.20% | 7.50 | 7.61 | 7.47 | Profile Chart News |